Why Goodyear's population boom makes postpartum depression care worth understanding locally
Goodyear grew by 46% between 2010 and 2020, adding roughly 30,000 residents in a single decade, and the growth hasn't slowed since. The city has topped 118,000 residents in recent estimates, up from just over 18,000 in 2000, and it consistently ranks among the fastest-growing cities in the country. That kind of expansion doesn't happen through retirees relocating for the winter. It happens through young families buying homes in master-planned communities, and a city growing that way inevitably has a growing population of new mothers navigating the period right after childbirth.
A city built to attract young families, and it's working
Estrella and Palm Valley, two of Goodyear's largest master-planned communities, were built around the kind of amenities that draw young households specifically, new construction, community pools, walkable schools, and resort-style shared spaces. Movoto has ranked Goodyear among the best Phoenix suburbs for young couples, and the city's own growth numbers back that reputation up. A community adding residents this quickly, this consistently, is adding new parents at a pace most Phoenix-area suburbs simply aren't.
Postpartum depression is common, and it's frequently missed
National data suggests roughly 1 in 8 women in the United States report symptoms of postpartum depression, with global prevalence estimates running higher, into the high teens as a percentage of new mothers. The gap between how common it is and how often it gets diagnosed is significant. Some research suggests close to half of postpartum depression cases go undiagnosed by healthcare providers, often because symptoms get attributed to normal new-parent exhaustion rather than a treatable medical condition. A fast-growing city with a steady stream of new parents is, by the numbers alone, generating a meaningful number of cases that never make it to a diagnosis at all.
What's actually FDA-approved for postpartum depression, and where ketamine fits differently
This is worth being precise about, because it's easy to assume ketamine-based treatment covers postpartum depression the same way it covers other forms of depression. It doesn't, at least not as an approved indication. The FDA has approved two medications specifically for postpartum depression: brexanolone, sold as Zulresso, a one-time IV infusion administered in a certified facility under close monitoring due to sedation risk, and zuranolone, sold as Zurzuvae, an oral medication approved in August 2023 that became the first pill specifically indicated for the condition. Neither of those is ketamine or esketamine.
The two approved options look very different from each other in practice. Brexanolone requires a multi-day inpatient-style infusion with continuous monitoring, including pulse oximetry, and patients have to be accompanied during any interaction with their baby while the infusion is running, all of which comes with a price tag that can run around $34,000 per treatment before insurance. Zuranolone, by contrast, is a once-daily oral pill taken in the evening for 14 days, a far less intensive protocol that helped drive its approval as the first take-home option built specifically for postpartum depression. Clinical guidelines still recommend psychotherapy as the first-line option for mild to moderate cases, reserving medication for more severe presentations.
Spravato's FDA approval covers treatment-resistant depression and major depressive disorder with suicidal ideation broadly, not postpartum depression as its own category. A new mother whose depression meets the criteria for treatment-resistant depression more generally may still be evaluated for Spravato or standard ketamine therapy, but that's a different clinical pathway than the medications built and approved specifically for the postpartum period. Getting that distinction right matters for anyone comparing treatment options rather than assuming every depression medication applies the same way across every diagnosis.
Getting evaluated in Goodyear
For a new parent in Goodyear weighing what postpartum depression treatment actually looks like, that starting point matters: whether the diagnosis is postpartum depression specifically or depression that happens to have emerged after childbirth but meets a broader treatment-resistant criteria. Kadelyx's ketamine therapy services for Goodyear begin with an evaluation that sorts out which category actually applies before recommending a path forward.
A city adding new families this fast was always going to need clear answers about postpartum mental health care, not just more general depression treatment options scaled up to meet demand.
